➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Moodys
Baxter
Mallinckrodt
Merck

Last Updated: September 19, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,342,477

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,342,477
Title: Remedies for thrombocytopenia
Abstract:Agents for preventing and treating thrombocytopenia, thrombocytopenic purpura and various diseases that tend to cause bleeding due, presumably, to thrombocytopenia contain a parathyroid hormone (PTH) or at least one PTH derivative as an active ingredient.
Inventor(s): Tamura; Masahiko (Shizuoka-ken, JP), Oda; Yasuhiro (Nagano-ken, JP)
Assignee: Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP)
Application Number:09/117,379
Patent Claims:1. A method for treating thrombocytopenia in a patient in need thereof, comprising administering to said patient an effective amount of a composition comprising parathyroid hormone (PTH) or a derivative thereof for a time and under conditions to ameliorate said thrombocytopenia.

2. The method according to claim 1, wherein human PTH (1-84) is administered.

3. The method according to claim 1, wherein human PTH (1-34) is administered.

4. The method according to claim 1 wherein said effective amount is in the range of 1 .mu.g to 1,000 .mu.g per kg of body weight administered systematically at a frequency ranging from once per day to once per month.

5. The method according to claim 1 wherein said effective amount is from 5 .mu.g to 200 .mu.g per kg of body weight administered from once every two weeks to once daily.

6. The method according to claim 1 wherein the route of said administration is subcutaneously.

7. The method according to claim 1 wherein the route of said administration is intravenously.

8. The method according to claim 1 wherein the route of said administration is intranasally.

9. The method according to claim 1 wherein the route of said administration is transpulmonarily.

10. The method of claim 1 wherein said PTH or PTH derivative is selected from the group consisting of human PTH (1-34), human PTH (1-64), human PTH (35-84), bovine PTH (1-34), human PTH (1-84), human PTH (1-38) and human PTH (1-37).

11. The method according to claim 1 wherein said PTH or PTH derivative modified with polyethylene glycol and administered.

12. The method according to claim 1 wherein said PTH or PTH derivative is administered encapsulated within microcapsules.

13. The method according to claim 1, wherein said PTH or PTH derivative is incorporated in a sheet of gel.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-16701Feb 1, 1996
PCT Information
PCT FiledFebruary 03, 1997PCT Application Number:PCT/JP97/00255
PCT Publication Date:August 07, 1997PCT Publication Number:WO97/27870

Details for Patent 6,342,477

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) 2016-02-01 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) 2016-02-01 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) 2016-02-01 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial Chugai Seiyaku Kabushiki Kaisha (Tokyo, JP) 2016-02-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
McKesson
Moodys
Colorcon
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.